Clinical Trial

A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC

Name: A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC — clinical trial record (NCT07385001)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined with Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for Resectable, Locally Advanced Esophageal Squamous Cell Carcinoma

Trial Details

NCT Number	NCT07385001
Lead Sponsor	Tang-Du Hospital
Conditions	Esophageal Squamous Cell Carcinoma, Ivonescimab, Neoadjuvant
Enrollment	45 participants
Start Date	2026-01-28
Primary Completion	2027-01-28 (estimated)
Study Completion	2028-01-28 (estimated)
Updated on ClinicalTrials.gov	2026-02-03